{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:45:46Z","timestamp":1792525546250,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jaci.2023.03.011","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T19:03:57Z","timestamp":1682103837000},"page":"1415-1428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-2946","authenticated-orcid":false,"given":"Michael E.","family":"Wechsler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Baylis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Roufosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2023.03.011_bib1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-015-8506-7","article-title":"Hypereosinophilic syndrome","volume":"50","author":"Curtis","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","article-title":"Update on eosinophilic granulomatosis with polyangiitis","volume":"68","author":"Furuta","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2023.03.011_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.iac.2015.04.002","article-title":"Spectrum of eosinophilic end-organ manifestations","volume":"35","author":"Akuthota","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2023.03.011_bib4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib5","first-page":"2125","article-title":"Clinical profile and treatment in hypereosinophilic syndrome variants: a pragmatic review","volume":"10","author":"Requena","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2023.03.011_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2023.03.011_bib8","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","article-title":"Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status","volume":"10","author":"Lyons","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2023.03.011_bib9","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.34067\/KID.0000502021","article-title":"Glucocorticoid therapy in ANCA vasculitis: using the glucocorticoid toxicity index as an outcome measure","volume":"2","author":"Floyd","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.jaci.2023.03.011_bib10","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaci.2023.03.011_bib11","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2023.03.011_bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fmed.2017.00216","article-title":"(A critical appraisal of) classification of hypereosinophilic disorders","volume":"4","author":"Kahn","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2023.03.011_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/1744666X.2019.1697678","article-title":"Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease","volume":"16","author":"Berti","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/acr2.11263","article-title":"Clinical manifestations and long-term outcomes of eosinophilic granulomatosis with polyangiitis in North America","volume":"3","author":"Doubelt","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.jaci.2023.03.011_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev-pathmechdis-012419-032756","article-title":"Contributions of eosinophils to human health and disease","volume":"15","author":"Klion","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jaci.2023.03.011_bib16","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"Gotlib","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2023.03.011_bib17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3324\/haematol.2009.021675","article-title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1","volume":"95","author":"Bain","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2023.03.011_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.26352","article-title":"World Health Organization\u2013defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2023.03.011_bib19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/all.12843","article-title":"Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha\u2013negative hypereosinophilic syndrome","volume":"71","author":"Khoury","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.03.011_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100809","article-title":"Hypereosinophilic syndromes\u2014an enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment","volume":"49","author":"Helbig","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jaci.2023.03.011_bib21","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3389\/fimmu.2020.01765","article-title":"Eosinophilia associated with CD3\u2212CD4+ T cells: characterization and outcome of a single-center cohort of 26 patients","volume":"11","author":"Carpentier","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib22","first-page":"1086","article-title":"CD3\u2212CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder","volume":"100","author":"Lef\u00e8vre","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2023.03.011_bib23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2023.03.011_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9095275","article-title":"Eosinophils from physiology to disease: a comprehensive review","volume":"2018","author":"Ramirez","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jaci.2023.03.011_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1084\/jem.170.1.343","article-title":"Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome","volume":"170","author":"Owen","year":"1989","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2023.03.011_bib26","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.4049\/jimmunol.139.11.3753","article-title":"T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome","volume":"139","author":"Raghavachar","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/JLB.5MR0118-028R","article-title":"Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)","volume":"104","author":"Khoury","year":"2018","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2023.03.011_bib28","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","author":"Valent","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.03.011_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/heartjnl-2015-307959","article-title":"Hypereosinophilic syndrome: cardiac diagnosis and management","volume":"102","author":"Mankad","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jaci.2023.03.011_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.19812","article-title":"Association of thrombosis with hypereosinophilic syndrome in patients with genetic alterations","volume":"4","author":"Leiva","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaci.2023.03.011_bib31","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2016.73","article-title":"Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2023.03.011_bib32","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1007\/s10067-021-05783-8","article-title":"Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis","volume":"40","author":"Jakes","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaci.2023.03.011_bib33","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib34","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.011_bib35","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/rheumatology\/kes171","article-title":"Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients","volume":"51","author":"Jakiela","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2023.03.011_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1196\/annals.1361.053","article-title":"Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome","volume":"1051","author":"Hellmich","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaci.2023.03.011_bib37","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/rheumatology\/keq445","article-title":"Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study","volume":"50","author":"Zwerina","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaci.2023.03.011_bib38","first-page":"863","article-title":"Eosinophilic granulomatosis with polyangiitis-related myocarditis during mepolizumab therapy reveals a Th1\/Th17-mediated vasculitic response","volume":"40","author":"Bello","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaci.2023.03.011_bib39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0","article-title":"Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome","volume":"44","author":"Kiene","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2023.03.011_bib40","first-page":"S23","article-title":"Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome","volume":"29","author":"Jakiela","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaci.2023.03.011_bib41","first-page":"445","article-title":"Antineutrophil cytoplasmic antibodies and organ-specific manifestations in eosinophilic granulomatosis with polyangiitis: a systematic review and meta-analysis","volume":"9","author":"Chang","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib42","article-title":"Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology","volume":"8","author":"Fagni","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2023.03.011_bib43","doi-asserted-by":"crossref","first-page":"iii84","DOI":"10.1093\/rheumatology\/kez570","article-title":"Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management","volume":"59","author":"Trivioli","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2023.03.011_bib44","first-page":"403","article-title":"Post-marketing surveillance of mepolizumab use in patients with eosinophilic granulomatosis with polyangiitis in Japan: interim analysis","volume":"42","author":"Fujii","year":"2021","journal-title":"Ther Res"},{"key":"10.1016\/j.jaci.2023.03.011_bib45","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202005-1628SO","article-title":"International consensus on ANCA testing in eosinophilic granulomatosis with polyangiitis","author":"Moiseev","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2023.03.011_bib46","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1093\/rheumatology\/keaa805","article-title":"Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"60","author":"Papo","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaci.2023.03.011_bib47","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ajpath.2020.03.005","article-title":"Pulmonary eosinophilic granulomatosis with polyangiitis has IgG4 plasma cells and immunoregulatory features","volume":"190","author":"Dong","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2023.03.011_bib48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/BOR.0000000000000015","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management","volume":"26","author":"Mahr","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaci.2023.03.011_bib49","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/rccm.201804-0809OC","article-title":"Sputum antineutrophil cytoplasmic antibodies in serum antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis","volume":"199","author":"Mukherjee","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2023.03.011_bib50","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/art.41722","article-title":"Occupational exposures and smoking in eosinophilic granulomatosis with polyangiitis: a case\u2013control study","volume":"73","author":"Maritati","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2023.03.011_bib51","first-page":"1496","article-title":"Eosinophilic granulomatosis with polyangiitis: clinical pathology conference and review","volume":"6","author":"Wu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib52","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.chest.2017.12.018","article-title":"The challenge of rare diseases","volume":"153","author":"Stoller","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2023.03.011_bib53","first-page":"113","article-title":"Eosinophils: offenders or general bystanders in allergic airway disease and pulmonary immunity?","volume":"3","author":"Akuthota","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2023.03.011_bib54","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.011_bib55","first-page":"2426","article-title":"CD3\u2212CD4+ lymphocytic variant hypereosinophilic syndrome: diagnostic tools revisited","volume":"9","author":"Carpentier","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib56","article-title":"Urine eosinophil-derived neurotoxin: a potential marker of activity in select eosinophilic disorders","author":"Makiya","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.03.011_bib57","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.jaip.2020.04.069","article-title":"Symptom assessment in hypereosinophilic syndrome: toward development of a patient-reported outcomes tool","volume":"8","author":"Kovacs","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.03.011_bib58","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2023.03.011_bib59","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2006.02.042","article-title":"Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report","volume":"117","author":"Klion","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib60","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1398-9995.2012.02873.x","article-title":"Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome","volume":"67","author":"Khoury","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.03.011_bib61","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jaip.2018.10.002","article-title":"C-reactive protein as a diagnostic tool in differential diagnosis of hypereosinophilic syndrome and antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis","volume":"7","author":"Leurs","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.03.011_bib62","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1378\/chest.108.2.320","article-title":"Formes frustes of Churg-Strauss syndrome","volume":"108","author":"Churg","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2023.03.011_bib63","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.23912","article-title":"Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score to assess survival in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 550 patients from Spain (REVAS registry)","volume":"72","author":"Solans-Laqu\u00e9","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jaci.2023.03.011_bib64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine"},{"key":"10.1016\/j.jaci.2023.03.011_bib65","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2023.03.011_bib66","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2017-212713","article-title":"Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire","volume":"77","author":"Robson","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2023.03.011_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121737","article-title":"Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"10","author":"Dejaco","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2023.03.011_bib68","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/rheumatology\/keu427","article-title":"Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis","volume":"54","author":"Grayson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2023.03.011_bib69","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.healun.2014.02.023","article-title":"Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)","volume":"33","author":"Groh","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jaci.2023.03.011_bib70","first-page":"18","article-title":"Cardiac involvement in eosinophilic granulomatosis with polyangiitis: a meta-analysis of 62 case reports","volume":"15","author":"Pakbaz","year":"2020","journal-title":"J Tehran Heart Center"},{"key":"10.1016\/j.jaci.2023.03.011_bib71","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/rheumatology\/keab514","article-title":"Revisiting characteristics, treatment and outcome of cardiomyopathy in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss)","volume":"61","author":"Sartorelli","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2023.03.011_bib72","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2023.03.011_bib73","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.03.011_bib74","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaci.2023.03.011_bib75","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib76","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.011_bib77","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.03.011_bib80","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.03.011_bib81","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/cea.13509","article-title":"Mechanisms of glucocorticoid resistance in hypereosinophilic syndromes","volume":"49","author":"Stokes","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2023.03.011_bib82","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/asheducation-2018.1.326","article-title":"Hypereosinophilic syndrome: approach to treatment in the era of precision medicine","volume":"2018","author":"Klion","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaci.2023.03.011_bib86","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib87","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.011_bib88","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.03.011_bib89","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/j.jval.2021.04.1143","article-title":"PSY2 Impact of mepolizumab on health-related quality of life in patients with hypereosinophilic syndrome","volume":"24","author":"von Maltzahn","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.jaci.2023.03.011_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840974","article-title":"Association between baseline therapy and flare reduction in mepolizumab-treated patients with hypereosinophilic syndrome","volume":"13","author":"Reiter","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib91","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.jaip.2022.04.037","article-title":"Mepolizumab reduces hypereosinophilic syndrome flares irrespective of blood eosinophil count and interleukin-5","volume":"10","author":"Rothenberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.03.011_bib92","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti\u2013interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.03.011_bib93","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","article-title":"Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials","volume":"43","author":"Samson","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2023.03.011_bib94","article-title":"Novel targets for drug use in eosinophilic granulomatosis with polyangiitis","volume":"8","author":"Uzzo","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2023.03.011_bib95","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2023.03.011_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000905","article-title":"Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"5","author":"Teixeira","year":"2019","journal-title":"RMD Open"},{"issue":"suppl\u00a010","key":"10.1016\/j.jaci.2023.03.011_bib97","article-title":"Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: a double-blind, randomized, controlled trial","volume":"73","author":"Terrier","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2023.03.011_bib98","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejim.2021.08.021","article-title":"Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis","volume":"95","author":"R\u00edos-Garc\u00e9s","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaci.2023.03.011_bib100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/mrcr\/rxab022","article-title":"Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Higashitani","year":"2022","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.jaci.2023.03.011_bib101","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.rmed.2010.09.011","article-title":"Lung involvement in hypereosinophilic syndromes","volume":"105","author":"Dulohery","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2023.03.011_bib102","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","article-title":"A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients","volume":"72","author":"Moosig","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2023.03.011_bib103","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1183\/13993003.00097-2016","article-title":"Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"48","author":"Cottin","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2023.03.011_bib104","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/acr.22686","article-title":"Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"68","author":"Durel","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jaci.2023.03.011_bib105","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.iac.2007.07.005","article-title":"Pulmonary eosinophilic syndromes","volume":"27","author":"Wechsler","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2023.03.011_bib106","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaci.2010.03.042","article-title":"Refining the definition of hypereosinophilic syndrome","volume":"126","author":"Simon","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.011_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine"},{"key":"10.1016\/j.jaci.2023.03.011_bib108","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00005792-198403000-00001","article-title":"Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome","volume":"63","author":"Lanham","year":"1984","journal-title":"Medicine"},{"key":"10.1016\/j.jaci.2023.03.011_bib109","first-page":"277","article-title":"Allergic granulomatosis, allergic angiitis, and periarteritis nodosa","volume":"27","author":"Churg","year":"1951","journal-title":"Am J Pathol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923003342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923003342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:41:54Z","timestamp":1758793314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674923003342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0091674923003342"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2023.03.011","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}